SLGL vs. AYTU, INDP, GLTO, VBIV, COCP, GLYC, KALA, NRBO, NERV, and TLPH
Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Aytu BioPharma (AYTU), Indaptus Therapeutics (INDP), Galecto (GLTO), VBI Vaccines (VBIV), Cocrystal Pharma (COCP), GlycoMimetics (GLYC), KALA BIO (KALA), NeuroBo Pharmaceuticals (NRBO), Minerva Neurosciences (NERV), and Talphera (TLPH). These companies are all part of the "pharmaceutical preparations" industry.
Sol-Gel Technologies (NASDAQ:SLGL) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
Aytu BioPharma has higher revenue and earnings than Sol-Gel Technologies. Aytu BioPharma is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
Aytu BioPharma received 108 more outperform votes than Sol-Gel Technologies when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 63.09% of users gave Sol-Gel Technologies an outperform vote.
Sol-Gel Technologies has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.23, indicating that its share price is 223% less volatile than the S&P 500.
Sol-Gel Technologies currently has a consensus target price of $8.00, suggesting a potential upside of 966.67%. Aytu BioPharma has a consensus target price of $5.00, suggesting a potential upside of 70.07%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Aytu BioPharma.
Aytu BioPharma has a net margin of -14.60% compared to Sol-Gel Technologies' net margin of -1,331.01%. Aytu BioPharma's return on equity of -31.31% beat Sol-Gel Technologies' return on equity.
In the previous week, Aytu BioPharma had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Aytu BioPharma and 1 mentions for Sol-Gel Technologies. Aytu BioPharma's average media sentiment score of 0.72 beat Sol-Gel Technologies' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 4.3% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Aytu BioPharma beats Sol-Gel Technologies on 10 of the 18 factors compared between the two stocks.
Get Sol-Gel Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sol-Gel Technologies Competitors List
Related Companies and Tools
